Waxman’s Cancer Act Renewal Legislation: More Pluses Than Minuses; Hearing Scheduled Feb. 25
In Brief: Search Committee Finds Prospects Uncertain About Election, Unwilling To Take Pay Cut
Intarferon Results Promising, ACS Says, And commits Another $3.4 Million
Randomization With Options Stimulates Sedmental Accrual
It’s Official; Most of NCI NTP contingent Will Move To N.C.
Guidelines Adopted For Pathology Review
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
